DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for dyskeratosis congenita, digenic — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDyskeratosis congenita, digenic maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dyskeratosis congenita, digenic is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
thymidylate synthetase (TYMS) — TYMS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3GH0 · 1.56 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Dyskeratosis congenita is a rare hereditary disease that occurs predominantly in males and manifests clinically as the classic triad of reticulate hyperpigmentation, nail dystrophy and leukoplakia. It increases the risk of malignancy and other potentially lethal complications such as bone marrow failure, lung and liver diseases. Mutations in 19 genes are associated with dyskeratosis congenita, and a fifth of the pathogenic mutations are found in DKC1, the gene coding for dyskerin. A 2002 report of two male patients in a Japanese kindred found a novel missense mutation L398P in the DKC1 gene. Despite harbouring the same mutation, one patient had significantly milder haematological symptoms than the other, indicating that other factors determine the severity of the disease.
A 2024 case study presents a 17-year-old male diagnosed with dyskeratosis congenita who presented with the classical triad of nail dystrophy, reticular skin pigmentation and oral leukoplakia, along with additional complications including dyspnoea, bilateral pedal oedema, and multiple pathological fractures. Despite an early diagnosis in 2018, the patient received no treatment until recent symptoms prompted further medical intervention. This case underscores the importance of early diagnosis and ongoing management to mitigate severe complications.
No drug treatment is mentioned in any of these abstracts. No clinical trial data, no response rates, no survival figures, and no repurposing candidates are reported. The literature review covers clinical and genetic aspects but does not evaluate any therapeutic intervention. The case study describes a patient who went untreated for years after diagnosis.
What is still missing is any evidence for a specific drug in dyskeratosis congenita, any clinical trial testing a repurposed agent, and any systematic effort to stratify patients by mutation type or severity. Without funding for such trials and without a molecular target validated in patients, no drug can be recommended from these data.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2020 · 63 citations
Dyskeratosis congenita: a literature review
AbstractDyskeratosis congenita is a rare hereditary disease that occurs predominantly in males and manifests clinically as the classic triad of reticulate hyperpigmentation, nail dystrophy and leukoplakia. It increases the risk of malignancy and other potentially lethal complications such as bone marrow failure, lung and liver diseases. Mutations in 19 genes are associated with dyskeratosis congenita, and a fifth of the pathogenic mutations are found in DKC1, the gene coding for dyskerin. This review aims to address the clinical and genetic aspects of the disease.
Pediatric Hematology and Oncology · 2002 · 20 citations
A NOVEL MISSENSE MUTATION IN THE DKC1 GENE IN A JAPANESE FAMILY WITH X-LINKED DYSKERATOSIS CONGENITA
AbstractThe authors report 2 male patients with dyskeratosis congenita (DC) in a Japanese kindred. Sequencing of the complementary DNA of the dyskerin gene (DKC1) revealed a T-to-C transition at nucleotide 1285 in exon 12 that resulted in a novel missense mutation L398P. Despite harboring the same mutation in the DKC1 gene, one patient had significantly milder hematological symptoms than the other, indicating that there may be other factors that determine the severity of DC.
International Journal of Science and Research (IJSR) · 2024 · 0 citations · open access
A Case Study of Dyskeratosis Congenita: Clinical Manifestations and Diagnostic Challenges
AbstractDyskeratosis congenita (DC), is a rare hereditary disorder predominantly affecting males and characterized by reticular skin pigmentation, nail dystrophy, and oral leukoplakia. This case study presents a 17 -year -old male diagnosed with DC, with classical triad of dystrophy of the nails, reticular skin pigmentation and oral leukoplakia along with additional complications including dyspnea, bilateral pedal edema, and multiple pathological fractures. Despite an early diagnosis in 2018, the patient received no treatment until recent symptoms prompted further medical intervention. This case underscores the importance of early diagnosis and ongoing management to mitigate the severe complications associated with DC.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
